Kennen Sie den Stellenwert der Pneumokokken-Serotypen 22F & 33F?

[1] Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkom-mission (STIKO) am RKI. Epid Bull 2016;36:351-384.
[2] Robert Koch-Institut (RKI). Schutzimpfung gegen Pneumokokken: Häufig gestellte Fragen und Antworten. Stand: 23.06.2020. https://www.rki.de/SharedDocs/FAQ/Impfen/Pneumokok-ken/FAQ-Liste_Pneumokokken_Impfen.html [eingesehen am 14.12.2022].
[3] Luck JN et al. Sugar-Coated Killer: Serotype 3 Pneumococcal Dis-ease. Front Cell Infect Microbiol. 2020;10:613287. DOI: 10.3389/fcimb.2020.613287.
[4] Akhter F et al. Hemoglobin Induces Early and Robust Biofilm Devel-opment in Streptococcus pneumoniae by a Pathway That Involves comC but Not the Cognate comDE Two-Component System. Infect Immun. 2021;89(4):e00779-20. DOI: 10.1128/IAI.00779-20.
[5] Sempere J et a l. Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain. Front Microbiol 2020;11:309. DOI: 10.3389/fmicb.2020.00309.
[6] Campoccia D et al. Extracellular DNA (eDNA). A Major Ubiquitous Element of the Bacterial Biofilm Architecture. Int J Mol Sci. 2021;22(16):9100. DOI: 10.3390/ijms22169100.
[7] Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB. Wie entstehen Biofilme? Stand 2022. Abrufbar unter: https://www.igb.fraunhofer.de/de/forschung/biofilme-und-hygi-ene/biofilme-charakterisierung-und-vermeidung/biofilme.html [eingesehen am 12.12.2022].
[8] Bajema KL et al. Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States. J Infect Dis. 2022;226(2):342-351. DOI: 10.1093/infdis/jiac154.
[9] Golden AR, et al. Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Can-ada: Focus on serotypes 22F and 33F from CANWARD 2007-2018. Vaccine. 2021;39(39):5474-5483. DOI: 10.1016/j.vac-cine.2021.08.061.
[10] van der Linden M et al. Limited indirect effects of an infant pneu-mococcal vaccination program in an aging population [published correction appears in PLoS One. 2020;15(1):e0228126]. PLoS One. 2019;14(8):e0220453. DOI: 10.1371/journal.pone.0220453.
[11] Fachinformation Prevenar®. Stand November 2020.
[12] Balsells E et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a system-atic review and meta-analysis. PLoS One. 2017;12(5):e0177113. DOI: 10.1371/journal.pone.0177113.
[13] European Centre for Disease Prevention and Control (ECDC). Inva-sive pneumococcal disease – Annual Epidemiological Report for 2018. Stand: 08.09.2020. Abgerufen unter: https://www.ecdc.eu-ropa.eu/en/publications-data/invasive-pneumococcal-disease-an-nual-epidemiological-report-2018 [eingesehen am 14.12.2022].
[14] Perniciaro S et al. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clin Infect Dis. 2022;75(7):1149-1153. DOI: 10.1093/cid/ciac100.
[15] Fachinformation VAXNEUVANCE®. Stand Oktober 2022.